Kendall Capital Partners

Name

Kendall Capital Partners

Legal name

Kendall Capital Partners

Website

https://kcpventures.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Venture Capital / Life Sciences Investment

NAICS

Portfolio Management and Investment Advice (52394), Investment Banking and Securities Intermediation (523150)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industries

Early-Stage Venture Capital (Series A/B) (FSANAAAB), Corporate Finance & Capital Advisory (BPAHADAB)

Keywords

• Venture capital investing
• Life sciences investment
• Healthcare venture capital
• Biotech startup funding
• Early-stage investments

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels3 records

Marketing channels3 records

Core offering

Kendall Capital Partners is a Boston-based venture capital firm that invests in early-to-commercial stage life sciences and healthcare companies. The firm deploys capital from institutional LPs, family offices, and HNWIs into biotech startups developing gene and cell therapies, next-generation immunotherapies, advanced drug delivery systems, and AI/computational biology platforms. Beyond capital, the firm provides scientific guidance, operational support, board-level governance, and exit planning to portfolio companies.

Product overview

Kendall Capital Partners is a venture capital firm that does not develop or sell its own products or services. It operates as an investment platform that provides capital, strategic guidance, and operational support to early-to-commercial stage life sciences and healthcare companies. The firm's portfolio companies include Eyenuk (AI eye screening), General Fluidics (point-of-care blood diagnostics), Centivax (universal vaccine technology), Bilayer Therapeutics (metabolic disorder treatments), Rejuvenate Bio (gene therapy for aging), and EpiBone (regenerative bone and cartilage technology).

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Investment Fund Venture capital fund deploying LP capital into early-to-commercial stage life sciences and healthcare companies developing breakthrough medical technologies across gene/cell therapies, immunotherapies, drug delivery, and AI/computational biology. Provides portfolio companies with capital, scientific guidance, board-level governance, and operational support.
• Portfolio Company Strategic Support Strategic and operational support services provided to portfolio companies throughout the company-building journey, including go-to-market strategy, board-level governance, pivotal hiring support, strategic pivot guidance, and pre-exit planning. Targeted at founders and management teams of portfolio biotech and healthcare companies.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Merck Animal HealthcoreStrategic or Co-development PartnerMerck Animal Health entered into a strategic R&D collaboration with Rejuvenate Bio to develop gene therapy programs targeting age-related diseases in companion animals. This is one of the world's largest animal health companies, signaling mainstream industry engagement with longevity biotechnology.
• Phibro Animal HealthcoreStrategic or Co-development PartnerRejuvenate Bio previously entered an agreement with Phibro Animal Health, validating the company's gene therapy technology and strategy for animal health applications prior to the Merck partnership.

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Flagship Pioneering: Cambridge-based biotech venture creation firm that originates and builds platform companies. Like Kendall, Flagship concentrates on breakthrough life sciences and has a deeply scientific partner bench (e.g., Noubar Afeyan), making it the most direct comparable in the sector-focused biotech VC category.
• Atlas Venture: Boston-based early-stage life sciences VC that builds biotech companies from inception through clinical proof-of-concept. Overlaps directly with Kendall on early-stage therapeutics, gene/cell therapy, and platform biotech investing in the Boston/Cambridge ecosystem.
• ARCH Venture Partners: Long-tenured biotech-focused VC investing across company formation, early, and growth stages. Comparable to Kendall as a sector-focused specialist backing transformative life sciences companies from frontier science through commercial milestones.
• OrbiMed: Healthcare-dedicated investment firm covering venture, growth, and public equity across therapeutics, medical devices, and diagnostics. Directly comparable as a healthcare-only specialist with a global LP base similar to Kendall's institutional and family office investors.
• RA Capital Management: Boston-based healthcare-focused investment manager operating a crossover fund and dedicated biotech venture strategy. Comparable to Kendall on Boston biotech focus, life sciences sector specialization, and crossover/private investing model.
• 5AM Ventures: Boston and San Francisco-based early-stage life sciences VC that builds companies around frontier science. Directly comparable as an early-stage sector specialist investing in therapeutics and platform technologies.
• Section 32: Venture fund founded by former Google Ventures head Bill Maris that invests broadly in technology and life sciences. Comparable as a sector-spanning investor with substantial biotech allocation and a founder-friendly approach to early-stage healthcare.

Broad incumbents

• Lux Capital: Tech-and-science focused VC that has built out life sciences and biotech investing alongside its broader AI and frontier-tech portfolio. Comparable as an investor in breakthrough science and AI/computational biology, though broader than Kendall's pure healthcare focus.
• Andreessen Horowitz (Bio + Health): Major venture firm with a dedicated Bio + Health practice investing across therapeutics, digital health, and biotech infrastructure. Comparable as a high-profile investor in frontier healthcare and AI-enabled biology, though operating as part of a much larger multi-sector platform.
• Alexandria Venture Investments: Strategic venture arm of Alexandria Real Estate Equities focused on life sciences companies across therapeutics, diagnostics, and research tools. Comparable as a life sciences sector specialist with deep relationships across biotech, though structured as a corporate CVC rather than an independent GP.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kendall Capital Partners